Intellia exits hemophilia B pact with Regeneron; Sangamo targets $24M raise
Plus, news about OKYO Pharma:
Intellia departs Regeneron deal: The CRISPR biotech disclosed Friday that it had opted out of a …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
